copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Bempedoic acid: Uses, Dosage, Side Effects, Warnings - Drugs. com Bempedoic acid (brand name Nexletol) is an oral, non-statin, LDL cholesterol-lowering treatment that may be used in adults to: lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in those unable to take recommended statin treatment (a cholesterol-lowering medicine), or are not taking a statin, who:
Bempedoic acid (oral route) - Side effects dosage - Mayo Clinic Description Bempedoic acid is used together with diet and other cholesterol-lowering medicines to reduce bad cholesterol (LDL) in patients with primary hyperlipidemia (high blood cholesterol), including heterozygous familial hypercholesterolemia (HeFH) Bempedoic acid is also used to lower the risk of heart attack and heart procedures (eg, stent placement or bypass surgery) in patients who are
Bempedoic acid: mechanism, evidence, safety, and guideline . . . Lowering low-density lipoprotein cholesterol remains foundational in reducing atherosclerotic cardiovascular disease Statins, ezetimibe, and PCSK9 inhibitors have established roles Bempedoic acid is an oral ATP‐citrate lyase (ACLY) inhibitor, relatively recently added to the lipid-lowering armamentarium In statin-intolerant or statin-suboptimal patients, plus in combination therapy, it
Efficacy of Bempedoic Acid, Novel Treatment for Elevated LDL . . . By Anthony Rice Bempedoic acid is a novel non-statin drug produced by Esperion Therapeutics to treat hypercholesterolemia, elevated levels of low-density lipoprotein (LDL) cholesterol in the blood 1 In the double-blind, placebo-controlled, phase 3 2022 CLEAR Outcomes trial conducted by Esperion, bempedoic acid treatment was associated with reductions in major adverse cardiovascular events
AACE Dyslipidemia Guidelines (2025 Updates) - Clinical Advisor The task force recommended against the use of bempedoic acid along with standard care among adults with dyslipidemia without ASCVD and with tolerance to other lipid-lowering medications
Bempedoic Acid - StatPearls - NCBI Bookshelf Bempedoic acid is a lipid-lowering agent pivotal in managing patients with elevated low-density lipoprotein cholesterol (LDL-C) levels The U S Food and Drug Administration (FDA) has sanctioned its use as an adjunct to maximally tolerated statin therapy for the reduction of LDL-C, specifically in individuals afflicted by atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial
Study Details | NCT07268625 | Evaluating Bioequivalence of a . . . A Randomized, Single-center, Open-label, Single-dose, 4-period, 2-sequence, Fully Replicate Crossover Study To Assess The Bioequivalence of A Test Fixed Dose Combination Product Versus The Co-administered Individual Reference Products Containing Bempedoic Acid 180 mg Ezetimibe 10 mg And Atorvastatin 40 mg In Healthy Participants
Nonstatin therapy to reduce low-density lipoprotein . . . In such instances, clinicians may consider nonstatin therapy to lower LDL cholesterol Nonstatin lipid-lowering agents including ezetimibe, proprotein convertase subtilisin kexin type 9 monoclonal antibodies, and bempedoic acid have been shown to reduce cardiovascular risk when given in conjunction with or in place of statins
First-In-Class Cholesterol-Lowering Treatment NILEMDO® Bempedoic acid is a first-in-class oral treatment which lowers cholesterol, and which can be combined with other treatments to help lower cholesterol even further